{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:44:22Z","timestamp":1790628262926,"version":"4.1.0"},"reference-count":33,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304629"],"award-info":[{"award-number":["82304629"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Teprotumumab, which targets the insulin-like growth factor-1 receptor, is the only drug approved by the US Food and Drug Administration (FDA) for the treatment of thyroid eye disease (TED).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to identify potential safety signals of teprotumumab by analyzing postmarketing safety data from the FDA Adverse Event Reporting System (FAERS) database in 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The case\/noncase approach was used to estimate the reporting odds ratio (ROR) and information component (IC) with relevant 95% CI for adverse events (AEs) that numbered 3 or more.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 2158 cases were included in the analysis. Main safety signals identified were ear and labyrinth disorders, reproductive system and breast disorders, metabolism and nutrition disorders, and gastrointestinal disorders. Specifically, autophony (ROR [95% CI] = 4188.34 [1403.29-12500.8]), eyelid retraction (ROR [95% CI] = 2094.17 [850.69-5155.29]), permanent deafness (ROR [95% CI] = 1552.35 [789.07-3053.98]), bilateral deafness (ROR [95% CI] = 73.12 [41.14-129.97]), inflammatory bowel disease (ROR [95% CI] = 23.26 [13.46-40.19]), hyperglycemic hyperosmolar nonketotic syndrome (ROR [95% CI] = 17.75 [5.70-55.28]), and amenorrhea (ROR [95% CI] = 47.98 [36.22-63.54]) showed significant safety signals with teprotumumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identified ear and labyrinth disorders, and reproductive system and breast disorders, as specific safety signals of teprotumumab. Clinicians and pharmacists should be vigilant regarding these AEs. However, available data are currently insufficient, and further pharmacovigilance and surveillance are needed to fully understand this issue.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgae417","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T11:49:05Z","timestamp":1718365745000},"page":"159-165","source":"Crossref","is-referenced-by-count":21,"title":["Postmarketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3302-5282","authenticated-orcid":false,"given":"Jing","family":"Huang","sequence":"first","affiliation":[{"name":"Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University , Chengdu 610041 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anping","family":"Su","sequence":"additional","affiliation":[{"name":"Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University , Chengdu 610041 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University , Chengdu 610041 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1720-8882","authenticated-orcid":false,"given":"Wei","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Women and Children's Hospital, School of Medicine, Xiamen University , Xiamen 361005 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1461-3954","authenticated-orcid":false,"suffix":"Sr","given":"Zhihui","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University , Chengdu 610041 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,6,15]]},"reference":[{"issue":"5","key":"2024121723533076800_dgae417-B1","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40265-020-01287-y","article-title":"Teprotumumab: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"issue":"4","key":"2024121723533076800_dgae417-B2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"2024121723533076800_dgae417-B3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1001\/jamaophthalmol.2021.6284","article-title":"Proptosis and diplopia response with teprotumumab and placebo vs the recommended treatment regimen with intravenous methylprednisolone in moderate to severe thyroid eye disease: a meta-analysis and matching-adjusted indirect comparison","volume":"140","author":"Douglas","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"16","key":"2024121723533076800_dgae417-B4","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves' disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"issue":"17","key":"2024121723533076800_dgae417-B5","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s40265-022-01804-1","article-title":"Teprotumumab: a review in thyroid eye disease","volume":"82","author":"Nie","year":"2022","journal-title":"Drugs"},{"issue":"1","key":"2024121723533076800_dgae417-B6","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1210\/er.2018-00066","article-title":"Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy","volume":"40","author":"Smith","year":"2019","journal-title":"Endocr Rev"},{"issue":"6","key":"2024121723533076800_dgae417-B7","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/jamaophthalmol.2022.1000","article-title":"Google searches for thyroid eye disease after regulatory approval of teprotumumab","volume":"140","author":"Strawbridge","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"2024121723533076800_dgae417-B8","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/cancers12040826","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting system database (FAERS)","volume":"12","author":"Cirmi","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2024121723533076800_dgae417-B9","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1365-2125.2011.04009.x","article-title":"Memory disorders associated with consumption of drugs: updating through a case\/noncase study in the French PharmacoVigilance database","volume":"72","author":"Chavant","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2024121723533076800_dgae417-B10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2165\/00002018-200225010-00002","article-title":"Case-population studies in pharmacoepidemiology","volume":"25","author":"Capell\u00e0","year":"2002","journal-title":"Drug Saf"},{"issue":"7","key":"2024121723533076800_dgae417-B11","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"issue":"6","key":"2024121723533076800_dgae417-B12","doi-asserted-by":"crossref","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief Bioinform"},{"issue":"10","key":"2024121723533076800_dgae417-B13","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3390\/nu10101512","article-title":"On the reporting of odds ratios and risk ratios","volume":"10","author":"Pace","year":"2018","journal-title":"Nutrients"},{"key":"2024121723533076800_dgae417-B14","author":"Huang","year":"2024"},{"issue":"6","key":"2024121723533076800_dgae417-B15","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/pds.3226","article-title":"Using time-to-onset for detecting safety signals in spontaneous reports of adverse events following immunization: a proof of concept study","volume":"21","author":"Van Holle","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"2024121723533076800_dgae417-B16","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2024121723533076800_dgae417-B17","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and Re-treatment: oPTIC-X study","volume":"129","author":"Douglas","year":"2022","journal-title":"Ophthalmology"},{"issue":"11","key":"2024121723533076800_dgae417-B18","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ophtha.2021.04.024","article-title":"Teprotumumab: interpreting the clinical trials in the context of thyroid eye disease pathogenesis and current therapies","volume":"128","author":"Winn","year":"2021","journal-title":"Ophthalmology"},{"issue":"8","key":"2024121723533076800_dgae417-B19","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1177\/00034894211042740","article-title":"Ototoxicity and teprotumumab","volume":"131","author":"Highland","year":"2022","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"9):","key":"2024121723533076800_dgae417-B20","doi-asserted-by":"crossref","first-page":"e654","DOI":"10.1210\/clinem\/dgad213","article-title":"Teprotumumab\u2014a review of its adverse effects profile","volume":"108","author":"Stan","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2024121723533076800_dgae417-B21","doi-asserted-by":"crossref","first-page":"1160936","DOI":"10.3389\/fendo.2023.1160936","article-title":"Efficacy and safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves' ophthalmopathy: a systematic review and meta-analysis","volume":"14","author":"Hu","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2024121723533076800_dgae417-B22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/bjc.2014.515","article-title":"A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1\/2 inhibitor, in advanced solid tumours","volume":"112","author":"Wilky","year":"2015","journal-title":"Br J Cancer"},{"issue":"2","key":"2024121723533076800_dgae417-B23","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1158\/1078-0432.CCR-15-0588","article-title":"Clinical and translational results of a phase II, randomized trial of an anti-IGF-1R (cixutumumab) in women with breast cancer that progressed on endocrine therapy","volume":"22","author":"Gradishar","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2024121723533076800_dgae417-B24","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1158\/1078-0432.CCR-09-3220","article-title":"A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors","volume":"16","author":"Kurzrock","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"34","key":"2024121723533076800_dgae417-B25","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2010.34.0000","article-title":"R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory ewing sarcoma family of tumors: results of a phase II sarcoma alliance for research through collaboration study","volume":"29","author":"Pappo","year":"2011","journal-title":"J Clin Oncol"},{"issue":"34","key":"2024121723533076800_dgae417-B26","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1200\/JCO.2011.36.6799","article-title":"Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer","volume":"29","author":"Ramalingam","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2024121723533076800_dgae417-B27","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1097\/IOP.0000000000002355","article-title":"Reduction of teprotumumab-induced hearing loss with comparable efficacy using half-dose therapy","volume":"39","author":"Phansalkar","year":"2023","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"2","key":"2024121723533076800_dgae417-B28","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/IOP.0000000000002078","article-title":"Rifle blast exacerbating hearing loss in a patient treated with teprotumumab for thyroid eye disease","volume":"38","author":"Reed","year":"2022","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"2","key":"2024121723533076800_dgae417-B29","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1097\/MAO.0000000000003428","article-title":"Sensorineural hearing loss after teprotumumab therapy for thyroid eye disease: a case report","volume":"43","author":"Ding","year":"2022","journal-title":"Otol Neurotol"},{"issue":"1","key":"2024121723533076800_dgae417-B30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/IOP.0000000000001995","article-title":"Teprotumumab and hearing loss: case series and proposal for audiologic monitoring","volume":"38","author":"Belinsky","year":"2022","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"1","key":"2024121723533076800_dgae417-B31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ophtha.2023.08.001","article-title":"Frequency and patterns of hearing dysfunction in patients treated with teprotumumab","volume":"131","author":"Keen","year":"2023","journal-title":"Ophthalmology"},{"issue":"8","key":"2024121723533076800_dgae417-B32","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.str.2022.05.007","article-title":"How insulin-like growth factor I binds to a hybrid insulin receptor type 1 insulin-like growth factor receptor","volume":"30","author":"Xu","year":"2022","journal-title":"Structure"},{"issue":"3","key":"2024121723533076800_dgae417-B33","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00280-013-2372-x","article-title":"Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies","volume":"73","author":"Mahadevan","year":"2014","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae417\/58464690\/dgae417.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/1\/159\/61213677\/dgae417.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/1\/159\/61213677\/dgae417.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T18:54:31Z","timestamp":1734461671000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/1\/159\/7693917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,15]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,6,15]]},"published-print":{"date-parts":[[2024,12,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae417","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,6,15]]}}}